Aspire Biopharma Holdings (ASBP) Return on Sales (2025 - 2026)

Aspire Biopharma Holdings (ASBP) posted quarterly Return on Sales of 1.14% for Q1 2026, up 94.01% quarter-over-quarter from 18.97% in Q4 2025.

Aspire Biopharma Holdings (ASBP) Return on Sales (2025 - 2026) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has reported Return on Sales for 2 consecutive years, with 1.14% the latest figure, recorded in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Aspire Biopharma Holdings	8.30 Mn	-3.86 Mn	-30,086.00	-0.20%

Download Data